GE HealthCare Technologies Inc. (GEHC) Covered Calls

GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator. Spun off from GE in 2023, the company operates through four segments: Imaging, Patient Care Solutions, Pharmaceutical Diagnostics, and Advanced Visualization. It provides advanced medical imaging, ultrasound, patient monitoring, and contrast media used in diagnosis and therapy. The firm leverages artificial intelligence to drive better patient outcomes and clinical efficiency.

You can sell covered calls on GE HealthCare Technologies Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GEHC (prices last updated Thu 4:16 PM ET):

GE HealthCare Technologies Inc. (GEHC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
78.65 -0.55 78.61 79.25 3.7M 17 36
Covered Calls For GE HealthCare Technologies Inc. (GEHC)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 79 0.05 79.20 -0.3% -12.2%
Mar 20 77.5 2.75 76.50 1.3% 12.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

GE HealthCare Technologies Inc. (GEHC) is a premier global medical technology innovator, serving as a critical pillar of the modern healthcare system. Following its successful transition to a pure-play healthcare company, it has focused on "precision care"—the integration of smart devices, digital apps, and pharmaceutical diagnostics to improve the efficiency and accuracy of patient screening, diagnosis, and treatment monitoring on a global scale.

Core Business and Products

  1. Imaging: This is the company’s largest segment, providing essential diagnostic equipment including computed tomography (CT), magnetic resonance (MRI), molecular imaging (PET/SPECT), and X-ray systems. In 2026, the company expanded this portfolio with the "Allia Moveo" platform, an AI-guided mobile C-arm designed for complex interventional procedures.
  2. Ultrasound: A global leader in ultrasound technology, the company offers specialized systems for radiology, cardiology, and women’s health. Its "Voluson" line remains a benchmark in maternal-fetal medicine, recently enhanced through AI-enabled collaborations with Diagnoly for real-time fetal heart and brain analysis.
  3. Patient Care Solutions: This division provides monitoring, anesthesia, and respiratory care systems. Strategic innovation includes a 2026 partnership with NXP Semiconductors to deploy "Edge AI" in acute care, enabling hands-free, voice-command interaction with anesthesia equipment and intelligent neonatal monitoring.
  4. Pharmaceutical Diagnostics: The company is a leading provider of contrast media and radiopharmaceuticals, which are injected into patients to enhance medical imaging. This segment is currently a high-growth driver, fueled by the global demand for molecular imaging and cancer screening.

Competitive Landscape

The medical technology sector is an innovation-led oligopoly. GE HealthCare’s most direct global rivals are Siemens Healthineers and Philips, with whom it shares the majority of the medical imaging market. In the surgical and monitoring space, it competes with Medtronic and Stryker. For diagnostic tools and consumables, it faces competition from Abbott Laboratories and Danaher. Additionally, as the company scales its digital and AI platforms, it increasingly faces pressure from specialized tech firms like Block for healthcare-adjacent payments and business management, and Google in the arena of health-data analytics.

Strategic Outlook and Innovation

In 2026, the company is executing its "Heartbeat" business system, a disciplined operational framework aimed at reducing backlogs and expanding margins toward 16%. A cornerstone of its strategy is the "Vivid Pioneer" cardiovascular ultrasound system, which leverages NVIDIA’s accelerated computing to process up to 50 times more data than traditional systems. Management is prioritizing a "vitality rate" strategy, ensuring that over 50% of annual revenue is derived from products launched within the last three years. Innovation is centered on "Agentic AI" through the AI Innovation Lab, which develops autonomous interpretation tools for mammography and cancer recurrence prediction. With over 70 FDA-authorized AI devices, the company is positioning itself as the "operating system" for hospitals, shifting from hardware sales to recurring revenue through software-as-a-service (SaaS) and multi-year enterprise agreements. The long-term goal remains focused on delivering 3-4% organic revenue growth while maintaining a fortress balance sheet for strategic acquisitions in the digital health space.